

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: FUJIMOTO, AKIHIDE ET
AL.

APPLICATION No.: 10/801,956

FILED: MARCH 15, 2004

FOR: **LOSS OF HETEROZYGOSITY OF THE
DNA MARKERS IN THE 12q22-23
REGION**

EXAMINER: STEVEN C.
POHNERT

ART UNIT: 1634

CONF. No: 2356

DECLARATION OF INVENTOR DAVE S.B. HOON UNDER 37 CFR 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Dave S.B. Hoon, declare as follows:

1. I am co-inventor of U.S. Patent Application Serial No. 10/801,956 ('956 Application). I am a full member of the John Wayne Institute for Cancer Treatment and Research and the Director of the Department of Molecular Oncology. I have been involved in the treatment and study of cancer for over 20 years. Presently, I am involved in molecular and surgical oncology translational research. My work involves the development of molecular/genetic surrogate biomarkers for assessment of cancer treatment responses, diagnosis, prognosis and staging of specific solid tumor cancers. One particular focus of my work is the assessment of molecular/genetic biomarkers such as circulating tumor cells and

circulating DNA in body fluids. Attached hereto is a copy of my current curriculum vitae.

2. I have reviewed the Office Action dated April 26, 2010 of the '956 Application, and in particular focused on the obviousness rejections of the pending claims based, in part, on Soengas et al. (Nature, 2001, volume 409, pages 207-211) which is referred to in this declaration as the "Soengas reference" or "Soengas." I have also reviewed the Soengas reference.

3. In accordance with the official guidelines by the American Joint Committee on Cancer (AJCC), Stage III melanoma is diagnosed by the presence of melanoma tumors that have spread to the regional lymph nodes or have developed in transit metastasis or satellites. According to the AJCC guidelines, Stage IV melanoma is diagnosed by melanoma tumors that have spread beyond the regional lymph nodes to distant sites in the body. The most common sites of metastasis are to the vital organs such as the brain, lungs, and abdominal organs and soft tissues. In contrast, Stage I and Stage II melanomas are not associated with metastasis.

4. The Soengas reference, in part, analyzes Apaf-1 expression and loss of heterozygosity (LOH) at the Apaf-1 locus in metastatic melanoma samples and the Apaf-1 expression in primary melanoma tumors (pp. 207-208), and Apaf-1 expression and Apaf-1 mutations in cell lines derived from metastatic melanomas (p. 208). In assessing LOH at the Apaf-1 locus, Soengas examined the LOH at microsatellite DNA markers D12S1657, D12S393, D12S1706, and D12S346. The

LOH at the markers was then associated with the expression or lack of expression of Apaf-1 by measuring mRNA (p. 207 Fig.1 (b)(c)).


5. Notably, Soengas does not teach or direct one of ordinary skill in the art to measure the LOH at microsatellite DNA markers D12S327, D12S1657, D12S393, D12S1706, and D12S346 from acellular DNA derived from the blood of a metastatic melanoma patient to predict the probability of survival, prognosis, or cancer therapy efficacy. One of ordinary skill in the art could not reasonably predict or assume that LOH of microsatellite DNA markers in a melanoma metastatic tumor would be the same in the acellular DNA derived from a metastatic melanoma patient's blood. For example, in Fujiwara et al., (Cancer Research, 1999, volume 59, pages 1567-1571) ("Fujiwara"), we demonstrated, that while LOH of microsatellite markers can be determined from acellular DNA, the LOH of microsatellite markers from informative metastatic melanoma tumors and informative acellular DNA from metastatic melanoma patients was not identical or predictable.

6. One of ordinary skill in the art would not be enabled, let alone expect to predict the probability of survival, prognosis, or cancer therapy efficacy based upon the LOH data in Soengas because as shown in Fujiwara, merely detecting LOH of a microsatellite marker does not predict prognosis, outcome or efficacy of treatment.

7. The method of using acellular DNA derived from patient blood to detect LOH provides a significant clinical advantage over LOH detection using tumor tissue because the method is non-invasive. This methodology provides a

particularly significant advantage to Stage IV patients as they often have inoperable tumors (e.g. brain tumors) that pose significant risk for biopsy.

I hereby declare under penalty of perjury under the laws of the United States of America that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Dave S.B. Hoon

12/8/2010
Date

CURRICULUM VITAE

Name: **DAVE S.B. HOON**

Wife: Hiroko

Date of Birth: 4/21/1955

Place of Birth: Victoria, British Columbia, Canada

Positions:

1997-present: Full Member, John Wayne Institute For Cancer Treatment and Research.

Director, Dept. Molecular Oncology.

1991-1996: Associate Member, John Wayne Institute Cancer Treatment and Research.

Director, Dept. Molecular & Cellular Immunology.

1988-1991: Assistant Professor, Division of Surgical Oncology, Department of Surgery,
U. of California Los Angeles School of Medicine, John Wayne Cancer Clinic.

1988-1994: Assistant Clinical Professor, Medical Surgical Section, U. of California Los Angeles
School of Nursing.

Postdoctoral Fellowship - Division of Surgical Oncology, Department of Surgery,

UCLA School of Medicine, 1983-86

Human tumor immunology

Research Oncologist - Division of Surgical Oncology, Department of Surgery,

UCLA School of Medicine, 1986-88.

Sabbaticals:

1994: Osaka Institute Molecular & Cellular Biology, Division Cellular Genetics,
Osaka University, Japan.

DEGREES

B.Sc. (Functional Biology) 4 year program, U. of Victoria, 1977.

Field of study - zoology

M.Sc. (Pathology) U. of Manitoba, Health Science, 1979.

Field of study - tumor virus cell biology

Ph.D (Microbiology, Immunology) U. of Saskatchewan, 1983.

Field of study - immune response to tumor metastasis

- Member of Canadian Armed Forces (Army Reserves); Commissioned officer, Rank: Captain (1973-1976).
- Member of Royal Canadian Mounted Police (1977-1978).

GRANT AWARDS

- Saskatchewan Health Research Board Scholarship (Ph.D)
- Canadian Cancer Society Fellowship
- Presidential California Cancer Award 1990
- Joseph Drown Foundation Award 1992, 1993, 1994, 1995
- Candle Foundation Award 1992
- NIH, NCI Program Project Surgery Immunology Immunotherapy (Project II Principal Investigator, Director): 1992-1997, Renewal, 1997-2002; Renewal 2002-2009; Renewal Submitted, 2009.

- NIH, NCI Program Project Surgery Immunology Immunotherapy (Molecular Core, Project II Principal Investigator, Director): 2002-2009; Renewal Submitted, 2009.
- NIH Program Project New Approaches to Surgery Oncology (Project II Principal Investigator, Director); 1993-1998; Renewal, 1998-2003; Renewal, 2003-2009; Renewal, 2009-2015.
- NIH Program Project New Approaches to Surgery Oncology (Molecular Core, Principal Investigator, Director); 2003-2009; Renewal, 2009-2015.
- US DOD Army Breast Cancer, 1996-1998, 2001-2003.
- California Breast Cancer Research Program, 1999-2001, 2001-2003, 2003-2007.
- Susan Komen Breast Cancer Foundation 2001-2003, 2004-2006, 2007-2010.
- US DOD Army Prostate Cancer, 2002-2006.
- USA DOD Army Prostate Cancer, 2007-2010.
- NIH NCI R21/R33 2003-2010.
- Avon Breast Research Foundation, 2005-2008
- Novartis Breast Clinical Trials, Biomarker Studies, 2007-2010.
- Adelson Melanoma Foundation (3 projects; PI, Co-PI), 2008-present
- Sysmex Phase III Breast Cancer Clinical Trials, Sentinel Node Molecular Staging, 2008-2009.
- Melanoma Research Alliance Team Program (MGH, Broad Institute, Stanford). Overall Project PI, 2008-2011.
- Abraxis HealthCare Sponsored Research Program PI, 2009-2012.
- Abraxis Phase III Clinical Trials, Biomarker Companion Studies, 2009-
- California Breast Cancer Research, 2010-2012.
- The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, 2010-2011.

DISTINGUISHED HONORS

- Boerhaave Honorary Professorship and Medal (Surgery Oncology) at Leiden University Medical Center (LUMC), Netherlands, 2010.

Current Research Focus

- Molecular and surgical oncology translational research. Development of molecular/genetic surrogate biomarkers for assessment of cancer treatment responses, diagnosis, prognosis and staging of specific solid tumor cancers. Emphasis on assessment of molecular/genetic biomarkers such as circulating tumor cells and circulating DNA in body fluids. Molecular staging of sentinel lymph node and tumors in melanoma, breast cancer, and colorectal cancer.
- Development of prognostic molecular/genetic biomarker companion studies in phase II and III multicenter clinical trials.
- Monitoring tumor immunotherapy response in patients.

TEACHING

- Laboratory teacher of clinical microbiology for nursing and pharmacy students (1979-1981). U. of Saskatchewan
- Laboratory teacher of basic immunology technique laboratory (1979-1982). U. of Saskatchewan.
- Consultant and assistant for graduate student seminar course, pathology 250A, UCLA, 1984.
- Teacher and supervisor for undergraduates, Biology 199, Microbiology 199 (research program 3rd and 4th yr), UCLA (1992-2004).
- Dean of Honors and Undergraduate programs, College of Letters and Science, UCLA. 1987-1991.
- Supervisor and instructor of UCLA SRP (student research program) for undergraduate science majors; 1988-2008.
- Teaching and advising medical students in surgery/oncology and immunology research series program, UCLA 1986-1991.
- Supervisor and teacher of medical students in UCLA Medical Students Summer Research Program 1985-89.
- Committee Member MSc. Thesis Dissertation: Stephanie Chang, RN, UCLA School of Nursing, Medical Surgical Section. 1990.
- Supervisor of medical student research program: 4th year medical school elective; 1985, 1988-1991.
- Research Program Supervisor/Mentor: Surgery Oncology Fellowship Board Certified Program (Senior and Junior): 1991-2010 (>20 fellows).
- Lecturer in Nursing Oncology 419, post-graduate program, UCLA School of Nursing, 1988-1995.
- Teaching 1st and 2nd year medicine electives: Developed course: Concepts in Vaccines. 1990.
- Teaching: UCLA Extension Course; Self and Non-self; The Human Immune System. 1991.
- Committee Member PhD: T. Nakayama, MD, Dept. Surgery, Osaka U. School of Medicine, Osaka, Japan. 2002.
- Supervisor and mentor, Undergraduate Research Fellows Program Award, Honors Collegium: Andy N. Tran, UCLA 2004; Melanie Wu, UCLA 2005; Terrance Yu, UCLA 2007.
- Supervisor and mentor: NIH Special Emphasis, Clinical Fellow Loans and Basic Research Program Fellowship, 2004-2007; Lori Wilson MD, Joseph Kim MD, Steve Martinez MD, Farin Amersi, MD.
- Mentor Advisor; AACR Mentor Program (New Investigators), AACR Annual Meeting, Anaheim, 2005; AACR Annual Meeting, Los Angeles, 2007; AACR Annual Meeting, San Diego, 2008.
- Committee Member, PhD: Ramin Shayan MBBS, Dept Surgery, University of Melbourne, Victoria, Australia. 2009.
- Committee Member and Supervisor, PhD: Michiel de Maat, MD, Dept of Surgery, Leiden University Medical Center, Leiden, Netherlands 2010.
- Committee Member and Supervisor, PhD: Anneke van Hoesel, Dept of Surgery, Leiden University Medical Center, Leiden, Netherlands 2010.

- Supervisor of laboratory research postdoctoral fellows (MD, MD/PhD, PhD), 1986-2010 (>40 fellows)

SOCIETY MEMBERSHIPS

- American Association of Immunology, American Association Clinical Oncology, American Society Gene Therapy, American Association Clinical Chemistry, American Association of Cancer Research, American Association Human Genetics, Federation of Experimental Biology, U. of Victoria alumni, U. of Manitoba alumni, U. of Saskatchewan alumni, U. of California, Los Angeles Medical alumni.

COMMITTEE MEMBERSHIPS

- Board Member: International Society of Sentinel Node 2000-2010
- Chairman/Organizer: Circulating Nucleic Acids in Plasma/Serum III and Serum Proteomics international meeting 2004, Santa Monica, CA.
- Faculty Board, International SLN Society, 2002-present
- External advisory committee Skin Spore, Wistar Institute U. of Pennsylvania, 2005- 2009.
- External advisory committee Skin Spore, M.D. Anderson, U. of Texas, 2005-present.
- External advisory committee Melanoma Program, Taussig Cancer Center, Cleveland, OH. 2008-present)
- Advisory Board, Omnimmune, 2006-present.
- Global advisory Board, Schering Plough, 2007-present: Treatment Monitoring Biomarkers.
- Advisory Board, Champions Biotechnology, 2007-present.
- Advisory Board, Bristol-Myers Squibb, 2008
- Advisory Board and CSO, OnCirc Biotechnology, 2009-present.
- Chairman/Organizer: 1st Gonda Sarcoma Symposium, Santa Monica, CA, December 2009.

PATENTS

- Issued:
 - Multimer RT-PCR assays for detection of metastatic melanoma and breast cancer cells (1999).
 - DNA cancer vaccines using HVJ and liposome delivery system(2001)
 - DNA microsatellite serum testing (2002)
 - RNA cancer vaccine using HVJ and liposome delivery system (2002)
 - New tumor associated gene, HOJ-1, chromosome 12 (2003)
 - Diagnostics and therapeutic patents (>20) (2003-present)
 - Licensed 20 patents (diagnostic & therapeutics) to Abraxis Pharmaceutical, 2009.
 - Licensed 3 patents (diagnostic) to OnCirc, 2009.

INSTITUTE ADMINISTRATION

- FDA protocol design, development and validation assays for vaccine product release for patient treatment (CancerVax), 2000-2002.
- Radiation Safety Officer, JWCI: 1992-2010. Radiation Safety Officer, CancerVax, Marina Del Rey: 2000-2002
- Scientific Review Committee JWCI (member) 2003-2010
- Director JWCI Educational Program 2006-2010

JOURNAL REVIEWER

Journals: Amer. J Pathol, Biomedicine, Biotechniques, Breast Cancer Research and Treatment British Journal Cancer, Cancer, Cancer Genes Chromosomes, Cancer Detection & Prevention, Cancer Immunol

Immunother., Cancer Letter, Cancer Res., Cell Death and Differentiation, Clin. Cancer Res., Clin Chem, Cytokine, Hepatology, Int. J. Cancer, J. Immunol., J. Immunol. Meth, J. Immunotherapy, J. Clin. Invest., J. Invest. Dermatology, J. Clin. Oncol., J. Nat.Cancer Inst., Lancet Oncology, Molecular Cancer Research, Molecular Therapy, Melanoma Res., Nature Clinical Oncology Rev, Nature Signaling Gateway Review, Neoplasia, New Engl. J. Med., Oncogene, Oncology, Pigment Res, Proc. Natl. Acad. Sci (USA).

STUDY SECTION AND INSTITUTE COMMITTEE REVIEWER

- Study section *ad hoc* member (Immunology); American Cancer Society, 1991.
- Study section *ad hoc* member (Experimental Immunology); NIH, NCI, 1994.
- Study section *ad hoc* member (Immunology) US Army Breast Cancer Task Force, 1996.
- Study section member NIH-NIAID, Innovation Program in HIV Vaccine Research, 1997.
- Study section member NIH-NIAID, Special Emphasis Panel: HIV pre-clinical/clinical vaccine, 1997.
- Dutch Cancer Society: Cancer Diagnosis Research Review Section 2000, 2004.
- The Cancer Research Campaign UK: Senior Clinical Research Fellowship Review, 2001.
- Study section member NIH, NCI, Special Emphasis Panel: Cancer Prognosis and Prediction 2001, 2002, 2004.
- Program Project Subcommittee C Review Group (*ad hoc*) NIH/NCI (Basic and Pre-Clinical), NIH, NCI (*ad hoc*); Site visits; 1998 (1), 1999 (1), 2000 (2), 2002 (1).
- Program Project Parent Subcommittee C Review Group (*ad hoc*) NIH/NCI (Basic and Pre-clinical) (*ad hoc*); 2000 (2), 2001 (1), 2002 (1).
- Program Project Parent Subcommittee C Review Group (*ad hoc*) NIH/NCI (Basic and Pre-Clinical), NIH, NCI, 2003-present, Permanent Member.
- Program Project Committee E Review NIH/NCI (*ad hoc*) (Cancer Prevention, Detection, Epidemiology), site visit 2002.
- Program Project Parent Subcommittee E Review Group (*ad hoc*) NIH/NCI (*ad hoc*)(Cancer Prevention, Detection, Epidemiology) (2002).
- The Cancer Research Campaign, UK. CRC Fellowship Program Review, 2001.
- NIH, NCI Spore (skin cancer) Committee 2001, 2003; Spore (GI and prostate cancer) Committee 2001; Spore (Breast) Committee 2002, 2005, 2006, 2007. Senior Member.
- NIH, NCI Study Section Special Emphasis Panel Loan Repayment NIH Committee, 2003.
- NIH, NCI Study Section Member Cancer Biomarkers, 2003-2006. Second term, 2007-present.
- NIH, NCI Resources to Advance Melanoma Research Committee, 2004.
- American Association Cancer Research Fellowship Awards Committee, 2003.
- NIH, NCI Study Section, Program Project Subcommittee C, Member 2003-present.
- NIH, NCI Study Section, Program Project Subcommittee D, (*ad hoc*) 2003.
- NIH, NCI, Study Section C, Chairman Study Review Cluster Program Project 2004.
- National Medical Research Council, Review Section, Singapore 2004.
- Research Grants Council, Hong Kong, China (2004, 2005).
- NIH, NCI, Study Section, Chairman, RFA CA 06-001, Circulating Cells and DNA in Cancer Detection, SBIR 2005.
- Centers of Cancer Nanotechnology Excellence, NCI, RFA, Special Emphasis Panel Member, 2005.
- Melanoma Research Program. Grant Review Panel. 2005.
- NCI, Cancer Center Review Group 2006.
- Cancer Genome Characterization Centers Review Committee, NCI, RFA, Special Emphasis Panel Member 2006.
- NCI-Avon Breast Review Committee, Special Emphasis Panel Member 2007.

- Adelson Medical Research Foundation (Melanoma) Executive Advisory Committee 2007.
- Breast Cancer Research Program CDRMP Clinical and Therapeutics Review 2008.
- Breast Cancer Research Program CDRMP Concept Awards Review 2009, 2010.
- NIH, SBIR/STTR, Small Business: Cancer Diagnostic and Therapeutics, 2010.
- Grant Review, Fondazione Cariplo, Milan, Italy, 2010.
- NCI, Drug Discovery, Biomarkers, and Therapeutics P01 Review Committee E, 2009-2010.

Peer-Reviewed Manuscripts

1. Balk SD, Mitchell RS, LeSturgeon D, **Hoon BS**. Thymidine and hypoxanthine requirements for the proliferation of normal and Rous sarcoma virus-infected chicken fibroblasts in the presence of methotrexate. *Cancer Res.* 39:1854-6, 1979.
2. Balk SD, Polimeni PI, **Hoon BS**, LeSturgeon DN, Mitchell RS. Proliferation of Rous sarcoma virus-infected, but not of normal, chicken fibroblasts in a medium of reduced calcium and magnesium concentration. *Proc Natl Acad Sci U S A.* 76:3913-6, 1979.
3. **Hoon BS**, Balk S, Mitchell RS, LeSturgeon D. Rapid, quantitative adipose conversion of chicken fibroblasts by high concentrations of chicken serum or plasma. *Experientia.* 35:1038-9, 1979.
4. Balk SD, **Hoon BS**, King GM, Loskutoff D, Mitchell RS, LeSturgeon DN, Weselake RJ. Rapid, reversible rounding and aggregation of Rous sarcoma virus-infected chicken fibroblasts induced by a plasma macromolecule. *Cancer Res.* 40:1753-60, 1980.
5. Ramshaw IA, Carlsen SA, **Hoon D**, Warrington RC. A 6-thioguanine-resistant variant of the 13762 cell line which is no longer tumorigenic or metastatic. *Int J Cancer.* 30(5):601-7, 1982.
6. **Hoon DB**, Ziola B, Carlsen S, Warrington R, Ramshaw I. Circulating immune complexes and immunoglobulin M-class rheumatoid factor in rats bearing mammary adenocarcinomas which vary in ability to metastasize. *Cancer Res.* 43(1):114-9, 1983.
7. **Hoon DB**, Ziola B, Ramshaw I. Circulating immune complexes in rats bearing 6-thioguanine-resistant variants of the 13762 mammary adenocarcinoma. *Cancer Res.* 44(6):2406-9, 1984.
8. **Hoon DB**, Wang HC, Ramshaw IA. Increased metastatic ability and bone formation of a mammary adenocarcinoma in vivo after in vitro passaging. *Eur J Cancer Clin Oncol.* 20:1517-26, 1984.
9. **Hoon DS**, Ramshaw IA. Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor. *Cancer Immunol Immunother.* 20:175-8, 1985.
10. **Hoon DB**, Ng SK, Ramshaw IA. Analysis of mammary tumour cell metastasis and release of bound n-acetylneuraminic acid. *Br J Cancer.* 51:775-81, 1985.
11. **Hoon DS**, Wen DR, Stene M, Gupta RK, Cochran AJ. Inhibition of lymphocyte motility by interleukin 2. *Clin Exp Immunol.* 66:566-73, 1986.
12. Cagle LA, **Hoon DSB**, Cochran AJ, Morton DL. Immunocompetence of draining lymph nodes of breast cancer. *Surg Forum* 37: 376-379, 1986.
13. **Hoon DS**, Ramshaw IA. A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic. *Cancer Immunol Immunother.* 24:42-8, 1987.
14. Cochran AJ, Pihl E, Wen DR, **Hoon DS**, Korn EL. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. *J Natl Cancer Inst.* 78:399-405, 1987.

15. **Hoon DS**, Bowker RJ, Cochran AJ. Suppressor cell activity in melanoma-draining lymph nodes. *Cancer Res.* 47:1529-33, 1987.
16. **Hoon DS**, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. *Cancer Res.* 47(6):1740-4, 1987.
17. Naeim F, **Hoon DS**, Cheng L, Herschman H, Cochran A Jr. Reactivity of neoplastic cells of hairy cell leukemia with antisera to S-100 protein. *Am J Clin Pathol.* 88:86-91, 1987.
18. Ando I, **Hoon DS**, Suzuki Y, Saxton RE, Golub SH, Irie RF. Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. *Int J Cancer.* 40:12-7, 1987.
19. Ando I, **Hoon DB**, Pattengail PK, Golub SH, Irie RF. Ganglioside GM2 as a target structure recognized by human natural killer cells. *J Clin Lab Anal.* 1: 209-213, 1987.
20. McBride WH, **Hoon DB**, Jung T, Naungayan J, Nizze A, Morton DL. Cyclophosphamide-induced alterations in human monocyte functions. *J Leukoc Biol.* 42:659-66, 1987.
21. Ibayashi Y, **Hoon DS**, Golub SH. The regulatory effect of adherent cells on lymphokine activated killer cells. *Cell Immunol.* 110:365-78, 1987.
22. Niku SD, **Hoon DS**, Cochran AJ, Morton DL. Isolation of lymphocytes from clotted blood. *J Immunol Methods.* 105:9-14, 1987.
23. **Hoon DS**, Irie RF, Cochran AJ. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. *Cell Immunol.* 111:410-9, 1988.
24. Hachida M, **Hoon DS**, Morton DL. A comparison of solutions for lung preservation using pulmonary alveolar type II cell viability. *Ann Thorac Surg.* 45:643-6, 1988.
25. Morton DL, Foshag LJ, Nizze JA, Gupta RK, Famatiga E, **Hoon DS**, Irie RF. Active specific immunotherapy in malignant melanoma. *Semin Surg Oncol.* 5:420-5, 1989.
26. Wen DR, **Hoon DS**, Chang C, Cochran AJ. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. *Cancer Immunol Immunother.* 30:277-82, 1989.
27. Klein JR, **Hoon DS**, Nangauyan J, Okun E, Cochran AJ. S-100 protein stimulates cellular proliferation. *Cancer Immunol Immunother.* 29:133-8, 1989.
28. **Hoon DS**, Jung T, Naungayan J, Cochran AJ, Morton DL, McBride WH. Modulation of human macrophage functions by gangliosides. *Immunol Lett.* 20:269-75, 1989.
29. **Hoon DS**, Ando I, Sviland G, Tsuchida T, Okun E, Morton DL, Irie RF. Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. *Int J Cancer.* 43:857-62, 1989.

30. Cochran AJ, Wen DR, Farzad Z, Stene MA, McBride W, Lana AM, **Hoon DS**, Morton DL. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. *Anticancer Res.* 9:859-64, 1989.
31. Yamamoto S, **Hoon DS**, Chandler P, Schmid I, Irie RF. Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells. *Cell Immunol.* 128:516-27, 1990.
32. **Hoon DBS**, Bowker R, Cochran AJ. Suppressor cell activity human breast cancer draining lymph nodes. *Surgical Res. Comm.* 9:167-176, 1990.
33. **Hoon DS**, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. *Cancer Res.* 50:5358-64, 1990.
34. Yamamoto S, Yamamoto T, Saxton RE, **Hoon DS**, Irie RF. Anti-idiotypic monoclonal antibody carrying the internal image of ganglioside GM3. *J Natl Cancer Inst.* 82:1757-60, 1990.
35. Economou JS, Hoban M, Lee JD, Essner R, Swisher S, McBride W, **Hoon DB**, Morton DL. Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. *Cancer Immunol Immunother.* 34:49-52, 1991.
36. **Hoon DS**, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. *Cancer Res.* 51:2002-8, 1991.
37. **Hoon DS**, Okun E, Banez M, Irie RF, Morton DL. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. *Cancer Res.* 51:5687-93, 1991.
38. Shibata M, **Hoon D**, Okun E, Morton D. Modulation of histamine type II receptors on CD8+ T cells by interleukin-2 and cimetidine. *Int Arch Allergy Immunol.* 97:8-16, 1992.
39. Hayashi Y, **Hoon DS**, Park MS, Terasaki PI, Morton DL. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. *Cancer Immunol Immunother.* 34:419-23, 1992.
40. Hayashi Y, **Hoon DS**, Park MS, Terasaki PI, Foshag LJ, Morton DL. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. *Cell Immunol.* 139:411-25, 1992.
41. **Hoon DS**, Kaback MM, Lim-Steele J, Tsuchida T, Morton DL, Irie RF. Ganglioside GM2 levels in human melanoma cells: inverse correlation with lysosomal beta-hexosaminidase A activity. *Biochem Int.* 27:343-52, 1992.
42. Morton DL, Foshag LJ, **Hoon DS**, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. *Ann Surg.* 216:463-82, 1992.

43. Morisaki T, Yuzuki DH, Lin RT, Foshag LJ, Morton DL, **Hoon DS**. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. *Cancer Res.* 52:6059-65, 1992.
44. Takeyama H, **Hoon DS**, Saxton RE, Morton DL, Irie RF. Growth inhibition and modulation of cell markers of melanoma by S-allyl cysteine. *Oncology.* 50:63-9, 1993.
45. Uchiyama A, Hoon DS, Morisaki T, Kaneda Y, Yuzuki DH, Morton DL. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. *Cancer Res.* 53:949-52, 1993.
46. Hayashi Y, **Hoon DS**, Foshag LJ, Park MS, Terasaki PI, Morton DL. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. *Cancer.* 72:750-9, 1993.
47. **Hoon DS**, Morisaki T, Uchiyama A, Hayashi Y, Foshag LJ, Nizze AJ, Morton DL. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens. *Ann N Y Acad Sci.* 690:343-5, 1993.
48. **Hoon DS**, Wang Y, Sze L, Kanda H, Watanabe T, Morrison SL, Morton DL, Irie RF. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. *Cancer Res.* 53:5244-50, 1993.
49. **Hoon DS**, Hayashi Y, Morisaki T, Foshag LJ, Morton DL. Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells. *Cancer Immunol Immunother.* 37:378-84, 1993.
50. **Hoon DS**, Okun E, Neuwirth H, Morton DL, Irie RF. Aberrant expression of gangliosides in human renal cell carcinomas. *J Urol.* 150:2013-8, 1993.
51. Morisaki T, Uchiyama A, Yuzuki D, Essner R, Morton DL, **Hoon DS**. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. *Cancer Res.* 54:1113-8, 1994.
52. Barth A, **Hoon DS**, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. *Cancer Res.* 54:3342-5, 1994.
53. Morisaki T, Morton DL, Uchiyama A, Yuzuki D, Barth A, **Hoon DS**. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma. *Cancer Immunol Immunother.* 39:172-8, 1994.
54. Morioka N, Kikumoto Y, **Hoon DS**, Morton DL, Irie RF. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. *J Immunol.* 153:5650-8, 1994.
55. **Hoon DS**, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. *J Immunol.* 154:730-7, 1995.
56. Morioka N, Kikumoto Y, **Hoon DS**, Morton DL, Irie RF. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. *Mol Immunol.* 32:573-81, 1995.

57. **Hoon DS**, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. *J Clin Oncol.* 13:2109-16, 1995.
58. **Hoon DS**, Doi F, Giuliano AE, Schmid P, Conrad AJ. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. *Cancer.* 76:533-5, 1995.
59. Doi F, Chi DD, Charuworn BB, Conrad AJ, Russell J, Morton DL, **Hoon DS**. Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. *Int J Cancer.* 65:454-9, 1996.
60. Uchiyama A, Essner R, Doi F, Nguyen T, Ramming KP, Nakamura T, Morton DL, **Hoon DS**. Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. *J Cell Biochem.* 62:443-53, 1996.
61. **Hoon DS**, Sarantou T, Doi F, Chi DD, Kuo C, Conrad AJ, Schmid P, Turner R, Guiliano A. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. *Int J Cancer.* 69:369-74, 1996.
62. Puri RK, **Hoon DS**, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated *Pseudomonas* exotoxin for therapy of malignant astrocytoma. *Cancer Res.* 56:5631-7, 1996.
63. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, **Hoon DS**. Melanoma-associated antigens as messenger RNA detection markers for melanoma. *Cancer Res.* 57:1371-6, 1997.
64. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, **Hoon DS**. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. *Am J Pathol.* 150:2143-52, 1997.
65. Takahashi T, Irie RF, Morton DL, **Hoon DS**. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. *Cell Immunol.* 178:162-71, 1997.
66. Takahashi T, Irie RF, Nishinaka Y, **Hoon DS**. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma. *Clin Cancer Res.* 3:1363-70, 1997.
67. Okamoto T, Kaneda Y, Yuzuki D, Huang SK, Chi DD, Hoon DS. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. *Gene Ther.* 4:969-76, 1997.
68. Essner R, Kuo CT, Wang H, Wen DR, Turner RR, Nguyen T, **Hoon DS**. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. *Cancer.* 82:309-16, 1998.

69. Kuo CT, Bostick PJ, Irie RF, Morton DL, Conrad AJ, **Hoon DS**. Assessment of messenger RNA of β -1,4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. *Clin Cancer Res.* 4:411-8, 1998.
70. **Hoon DS**, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? *J Clin Oncol.* 16:1430-7, 1998.
71. Nishinaka Y, **Hoon DS**, Irie RF. Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups. *Immunogenetics.* 48:73-5, 1998.
72. O'Connell CD, Juhasz A, Kuo C, Reeder DJ, **Hoon DS**. Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. *Clin Chem.* 44:1161-9, 1998.
73. Zhang Z, Irie RF, Chi DD, **Hoon DS**. Cellular immuno-PCR. Detection of a carbohydrate tumor marker. *Am J Pathol.* 152:1427-32, 1998.
74. Takahashi T, Conforti A, Kikumoto Y, **Hoon DS**, Morton DL, Irie RF. Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine. *J Clin Immunol.* 18:299-305, 1998.
75. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, **Hoon DS**. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. *J Clin Oncol.* 16:2632-40, 1998.
76. Huang SK, Okamoto T, Morton DL, **Hoon DS**. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. *J Invest Dermatol.* 111:662-7, 1998.
77. Bostick PJ, **Hoon DS**, Cote RJ. Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer. *N Engl J Med.* 339:1643-4, 1998.
78. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, **Hoon DS**. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. *J Invest Dermatol.* 111:1034-9, 1998.
79. Bostick PJ, Huynh KT, Sarantou T, Turner RR, Qi K, Giuliano AE, **Hoon DS**. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. *Int J Cancer.* 79:645-51, 1998.
80. Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R, **Hoon DS**. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. *Cancer Res.* 59:1567-71, 1999.
81. Takahashi T, Cao J, **Hoon DS**, Irie RF. Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. *Br J Cancer.* 81:342-9, 1999.

82. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, Essner R, **Hoon DS**. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. *J Clin Oncol*. 17:3238-44, 1999.
83. Zhou WZ, Kaneda Y, Huang S, Morishita R, **Hoon D**. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. *Gene Ther*. 6:1768-73, 1999.
84. Zhou WZ, **Hoon DS**, Huang SK, Fujii S, Hashimoto K, Morishita R, Kaneda Y. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. *Hum Gene Ther*. 10:2719-24, 1999.
85. Essner R, Huynh Y, Nguyen T, Morton DL, **Hoon DS**. Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: novel targets for immune therapy. *J Thorac Cardiovasc Surg*. 119:10-20, 2000.
86. Fujiwara Y, **Hoon DS**, Yamada T, Umeshita K, Gotoh M, Sakon M, Nishisho I, Monden M. PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. *Jpn J Cancer Res*. 91:287-92, 2000.
87. Bilchik A, Miyashiro M, Kelley M, Kuo C, Fujiwara Y, Nakamori S, Monden M, **Hoon DS**. Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay. *Cancer*. 88:1037-44, 2000.
88. **Hoon DS**, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. *Cancer Res*. 60:2253-7, 2000.
89. Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ, Nemunaitis J, **Hoon DS**. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. *Cancer Gene Ther*. 7:1220-30, 2000.
90. Fujiwara Y, **Hoon DS**. Microsatellite analysis of melanoma lesions using (CA)13 oligonucleotides as an internal probe. *Int J Oncol*. 17:783-7, 2000.
91. Essner R, Huynh Y, Nguyen T, Rose M, Kojima M, **Hoon DS**. Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy. *J Gastrointest Surg*. 5:81-90, 2001.
92. Bilchik AJ, Saha S, Wiese D, Stonecypher JA, Wood TF, Sostrin S, Turner RR, Wang HJ, Morton DL, **Hoon DS**. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. *J Clin Oncol*. 19:1128-36, 2001.
93. Miyashiro I, Kuo C, Huynh K, Iida A, Morton D, Bilchik A, Giuliano A, **Hoon DS**. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. *Clin Chem*. 47:505-12, 2001.
94. Nakayama T, Taback B, Turner R, Morton DL, **Hoon DS**. Molecular clonality of in-transit melanoma metastasis. *Am J Pathol*. 158:1371-8, 2001.

95. Turner RR, Giuliano AE, **Hoon DS**, Glass EC, Krasne DL. Pathologic examination of sentinel lymph node for breast carcinoma. *World J Surg.* 25:798-805, 2001.
96. Kobayashi H, Song Y, **Hoon DS**, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. *Cancer Res.* 61:4773-8, 2001.
97. **Hoon DS**, Kuo CT, Wascher RA, Fournier P, Wang HJ, O'Day SJ. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. *J Invest Dermatol.* 117:375-8, 2001.
98. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, **Hoon DS**. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. *Cancer Res.* 61:5723-6, 2001.
99. **Hoon DS**, Kuo CT, Wen S, Wang H, Metelitsa L, Reynolds CP, Seeger RC. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. *Am J Pathol.* 159:493-500, 2001.
100. Wascher RA, Bostick PJ, Huynh KT, Turner R, Qi K, Giuliano AE, **Hoon DS**. Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. *Br J Cancer.* 85:1340-6, 2001.
101. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, **Hoon DS**. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. *Cancer Res.* 61:8845-50, 2001.
102. Sugita Y, Fujiwara Y, **Hoon DS**, Miyamoto A, Sakon M, Kuo CT, Monden M. Overexpression of beta 1,4N-acetylgalactosaminyl- transferase mRNA as a molecular marker for various types of cancers. *Oncology.* 62:149-56, 2002.
103. Tanaka M, Kaneda Y, Fujii S, Yamano T, Hashimoto K, Huang SK, **Hoon DS**. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. *Mol Ther.* 5:291-9, 2002.
104. Bilchik AJ, Nora D, Tollenaar RA, van de Velde CJ, Wood T, Turner R, Morton DL, **Hoon DS**. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. *Eur J Cancer.* 38:977-85, 2002.
105. Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, **Hoon DS**, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. *Ann Surg.* 236:438-48, 2002.
106. Taback B, Hashimoto K, Kuo CT, Chan A, Giuliano AE, **Hoon DS**. Molecular lymphatic mapping of the sentinel lymph node. *Am J Pathol.* 161:1153-61, 2002.

107. Bilchik AJ, Nora DT, Saha S, Turner R, Wiese D, Kuo C, Ye X, Morton DL, **Hoon DS**. The use of molecular profiling of early colorectal cancer to predict micrometastases. *Arch Surg*. 137:1377-83, 2002.
108. Takeuchi H, Kuo C, Morton DL, Wang HJ, **Hoon DS**. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. *Cancer Res*. 63:441-8, 2003.
109. Yamamoto S, Yamano T, Tanaka M, **Hoon DS**, Takao S, Morishita R, Aikou T, Kaneda Y. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. *Cancer Gene Ther*. 10:179-86, 2003.
110. Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D, **Hoon DS**. Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. *Clin Cancer Res*. 9:1427-35, 2003.
111. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ, **Hoon DS**. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. *Clin Cancer Res*. 9:1480-8, 2003.
112. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, **Hoon DS**. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. *Cancer Res*. 63:1639-43, 2003.
113. Taback B, Giuliano AE, Hansen NM, Singer FR, Shu S, **Hoon DS**. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. *Cancer Res*. 63:1884-7, 2003.
114. Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang HJ, Gerami M, **Hoon DS**. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. *J Clin Oncol*. 21:2558-63, 2003.
115. Kuo CT, **Hoon DS**, Takeuchi H, Turner R, Wang HJ, Morton DL, Taback B. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. *J Clin Oncol*. 21:3566-72, 2003.
116. Morton DL, **Hoon DS**, Cochran AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, Bilchik AJ, Elashoff D, Elashoff R. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. *Ann Surg*. 238:538-49, 2003.
117. Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R, Wang HJ, **Hoon DS**. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. *J Natl Cancer Inst*. 96:152-6, 2004.
118. Shinozaki M, Fujimoto A, Morton DL, **Hoon DS**. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. *Clin Cancer Res*. 10:1753-7, 2004.

119. Takeuchi H, Taback B, Kuo C, **Hoon DS**. Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy. *Ann Surg Oncol*. 11:152S-5S, 2004.
120. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, **Hoon DS**. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. *Cancer Res*. 64:2245-50, 2004.
121. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, **Hoon DS**. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. *Clin Cancer Res*. 10:2351-8, 2004.
122. Umetani N, **Hoon DS**. Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma. *Brain Pathol*. 14:224, 2004.
123. **Hoon DS**, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. *Oncogene*. 23:4014-22, 2004.
124. Fujimoto A, O'Day SJ, Taback B, Elashoff D, **Hoon DS**. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. *Cancer Res*. 64:4085-8, 2004.
125. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, Taback B, Fujimoto A, **Hoon DS**. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. *J Clin Oncol*. 22:2671-80, 2004.
126. Taback B, Bilchik AJ, Saha S, Nakayama T, Wiese DA, Turner RR, Kuo CT, **Hoon DS**. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. *Int J Cancer*. 111:409-14, 2004.
127. Umetani N, Fujimoto A, Takeuchi H, Shinozaki M, Bilchik AJ, **Hoon DS**. Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma. *Oncogene*. 23:8292-300, 2004.
128. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, **Hoon DS**. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. *Clin Cancer Res*. 10:7475-83, 2004.
129. **Hoon DS**. Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma? *Nat Clin Pract Oncol*. 1:74-5, 2004.
130. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, Koyanagi K, **Hoon DS**. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. *Cancer Res*. 65:1800-7, 2005.
131. Shinozaki M, **Hoon DS**, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. *Clin Cancer Res*. 11:2156-62, 2005.

132. Umetani N, de Maat MF, Mori T, Takeuchi H, **Hoon DS**. Synthesis of universal unmethylated control DNA by nested whole genome amplification with *phi29* DNA polymerase. *Biochem Biophys Res Commun*. 329:219-23, 2005.
133. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, **Hoon DS**. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. *J Clin Oncol*. 23:2744-53, 2005.
134. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, Wang HJ, Hseuh E, O'Day SJ, **Hoon DS**. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. *Clin Chem*. 51:981-8, 2005.
135. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, **Hoon DS**. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. *Oncogene*. 24:4721-7, 2005.
136. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, **Hoon DS**. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. *J Clin Oncol*. 23:8057-64, 2005.
137. Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, Bilchik A, Turner R, Tran A, Kuo C, **Hoon DS**. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. *Clin Cancer Res*. 11:7621-8, 2005.
138. Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, Hines OJ, Reber HA, **Hoon DS**, Eibl G. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. *Cancer Res*. 65:11536-44, 2005.
139. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, Vu VD, Nguyen SL, **Hoon DS**. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. *J Clin Oncol*. 23:9351-8, 2005.
140. Takeuchi H, Morton DL, Elashoff D, **Hoon DS**. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. *Int J Cancer*. 117:1032-8, 2005.
141. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, **Hoon DS**. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. *Mol Ther*. 13:194-202, 2006.
142. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL, **Hoon DS**. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. *Clin Cancer Res*. 12:1137-43, 2006. Editorial: 1069-1073.
143. Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, Murata H, Takata M, Aburatani H, **Hoon DS**, Saida T, Kawakami Y. A new melanoma antigen fatty acid-binding protein 7,

involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. *Cancer Res.* 66:4443-9, 2006.

144. Umetani N, de Maat MF, Sunami E, Hiramatsu S, Martinez S, **Hoon DS**. Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation. *Mol Cancer Res.* 4:303-9, 2006.
145. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X, Amersi FF, Martinez SR, Dry SM, Bilchik AJ, **Hoon DS**. The clinical significance of MAGEA3 expression in pancreatic cancer. *Int J Cancer.* 118:2269-75, 2006.
146. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, **Hoon DS**. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. *Clin Chem.* 52:1062-9, 2006.
147. Bilchik AJ, DiNome M, Saha S, Turner RR, Wiese D, McCarter M, **Hoon DS**, Morton DL. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. *Arch Surg.* 141:527-33, 2006.
148. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, **Hoon DS**. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. *Cancer Res.* 66:6111-7, 2006.
149. Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ, **Hoon DS**. Estrogen receptor-alpha methylation predicts melanoma progression. *Cancer Res.* 66:6692-8, 2006.
150. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, **Hoon DS**. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. *Ann Surg.* 244:113-20, 2006.
151. Mocellin S, **Hoon D**, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. *Clin Cancer Res.* 12:4605-13, 2006.
152. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, **Hoon DS**. Prediction of breast tumor progression by integrity of free circulating DNA in serum. *J Clin Oncol.* 24:4270-6, 2006.
153. Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu S, Bilchik AJ, Yong S, Shoup M, **Hoon DS**. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. *Gut.* 55:1598-605, 2006.
154. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, **Hoon DS**. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. *Ann Surg.* 244:799-804, 2006.

155. Boasberg PD, **Hoon DS**, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. *J Invest Dermatol.* 126:2658-63, 2006.
156. Nakagawa T, Huang SK, Martinez SR, Tran AN, Elashoff D, Ye X, Turner RR, Giuliano AE, **Hoon DS**. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. *Cancer Res.* 66:11825-30, 2006.
157. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ, **Hoon DS**. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. *Clin Cancer Res.* 13:2068-74, 2007.
158. Mocellin S, **Hoon DS**, Pilati P, Rossi CR, Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. *J Clin Oncol.* 25:1588-95, 2007.
159. de Maat MF, Umetani N, Sunami E, Turner RR, **Hoon DS**. Assessment of Methylation Events during Colorectal Tumor Progression by Absolute Quantitative Analysis of Methylated Alleles. *Mol Cancer Res.* 5:461-71, 2007.
160. Takeuchi H, Greep NC, **Hoon DS**, Giuliano AE, Hansen NM, Umetani N, Singer FR. Hypermethylation of adenosine triphosphate-binding cassette transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging. *J Clin Endocrinol Metab.* 92:1785-90, 2007.
161. Yamano T, Kaneda Y, Hiramatsu SH, Huang S, Tran AN, Giuliano AE, **Hoon DS**. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. *Cancer Gene Ther.* 14:451-9, 2007.
162. Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, **Hoon DSB**. Detection of Circulating Tumor Cells in Early Stage Breast Cancer Metastasis to Axillary Lymph Nodes. *Clin Cancer Res.* 13:4105-10, 2007.
163. de Maat M, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar RA, **Hoon DS**. Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. *J Clin Oncol.* 25:4887-94, 2007. Editorial 4865–4867.
164. Bilchik AJ, **Hoon DSB**, Saha S, DiNome M, Turner R, Koyanagi K, McCarter M, Shen P, Iddings D, Elashoff D, Morton DL. Prognostic Impact of Micrometastases in Colon Cancer: Interim Results of a Prospective Multicenter Trial. *Ann Surg.* 246:568-75, 2007.
165. Amersi FF, Terando AM, Goto Y, Scolyer RA, Thompson JF, Tran AN, Faries MB, Morton DL, and **Hoon DSB**. Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. *Clin Cancer Res.* 14:638-645, 2008. Editorial: 621-623.
166. de Maat M, van de Velde CJ, van der Werff MP, Putter H, Umetani N, Klein-Kranenburg EM, Turner RR, van Krieken JH, Bilchik AJ, Tollenaar RA, **Hoon DS**. Quantitative Analysis of

167. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, **Hoon DSB**. Human High Molecular Weight–Melanoma-Associated Antigen: Utility for Detection of Metastatic Melanoma in Sentinel Lymph Nodes. *Clin Cancer Res.* 14:3401-7, 2008
168. Rhodes EC, Johnson-Pais TL, Singer FR, Ankerst DP, Bruder JM, Wisdom J, **Hoon DS**, Lin E, Bone HG, Simcic KJ, Leach RJ. Sequestosome 1 (SQSTM1) Mutations in Paget's Disease of Bone from the United States. *Calcif Tissue Int.* 82:271-7, 2008.
169. Sunami E, Shinozaki M, Sim M, Nguyen SL, Vu A, Giuliano AE, **Hoon DSB**. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. *Breast Cancer Res.* 10:R46, 2008.
170. Karim RZ, Scolyer RA, Li W, Yee VS, McKinnon JG, Li LX, Uren RF, Lam S, Beavis A, Dawson M, Doble P, **Hoon DS**, Thompson JF. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. *Ann Surg.* 247:1003-10, 2008.
173. Koyanagi K, Bilchik AJ, Saha S, Turner RR, Wiese D, McCarter M, Shen P, Deacon L, Elashoff D, **Hoon DS**. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. *Clin Cancer Res.* 14:7391-6, 2008
174. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, **Hoon DS**. Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. *Mol Cancer Ther.* 7:3642-53, 2008.
175. Tanemura A, Terando A, Sim M, van Hoesel A, de Maat M, Morton DL, **Hoon DS**. CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma. *Clin Cancer Res.* 15: 1801-7, 2009.
176. Sato Y, Goto Y, Narita N, Hoon DSB. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. *Cancer Microenviron.* 2 (Suppl 1): 205-214, 2009.
177. Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Singer FR, **Hoon DS**. Multimarker Circulating DNA Assay for Assessing Blood of Prostate Cancer Patients. *Clin Chem.* 55:559-67, 2009.
178. Huang SK, Darfler MM, Nicholl MB, You J, Bemis KG, Tegeler TJ, Wang M, Wery JP, Chong KK, Nguyen L, Scolyer RA, and **Hoon DS**. LC/MS-based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis. *PLoS ONE.* 4: e4430, 2009.
179. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, Morton DL, Soldano F, **Hoon DS**. mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads. *Clin Chem.* 55:757-764, 2009

180. Kitago M, Martinez SR, Nakamura T, Sim MS, **Hoon DS**. Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma. *Clin Cancer Res*. 15:2988-94, 2009.
181. Narita N, Tanemura A, Murali R, Scolyer RA, Huang S, Arigami T, Yanagita S, Chong KK, Thompson JF, Morton DL, and **Hoon DS**. Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma. *Oncogene*. 28:3058-3068, 2009.
182. Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, Nguyen L, Nguyen T, Ye X, Morton DL, **Hoon DS**. Aberrant Fatty Acid-Binding Protein 7 Gene Expression In Cutaneous Malignant Melanoma. *J Invest Dermatol*. 130:221-9, 2010.
183. Izraely S, Klein A, Sagi-Assif O, Meshel T, Tsarfaty G, **Hoon DSB** and Witz IP. Chemokine-Chemokine Receptor Axes in Melanoma Brain Metastasis. *Immunol Lett*. 130(1-2):107-14, 2010.
184. Goto Y, Arigami T, Murali R, Scolyer RA, Tanemura A, Takata M, Turner RR, Nguyen L, Nguyen T, Morton DL, Ferrone S, **Hoon DSB**. High Molecular Weight-Melanoma-Associated Antigen as a Biomarker of Desmoplastic Melanoma. *Pigment Cell Melanoma Res*, 23:137-140, 2010.
185. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, Giuliano A, **Hoon DS**. B7-H3 Ligand expression by primary breast cancer and associated with regional nodal metastasis. *Ann Surg*. 252:1044-51, 2010.
186. Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersch E, Richards J, Weber JS, **Hoon DS**. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. *Clin Cancer Res*, 16:2402-2408, 2010.
187. de Maat M, van de Velde CJ, Bernard A, Putter H, Morreau H, van Krieken JH, Klein-Kranenburg E, de Graaf EJ, Tollenaar RA, **Hoon DS**. Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer. *Clin Cancer Res*, 16: 2811-2818, 2010. Editorial: 2699-2701.
188. Nicholl MB, Elashoff D, Takeuchi H, Morton DL, **Hoon DS**. Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients. *Ann Surg (in press)*, 2010.
189. de Maat MFG, Narita N, Benard A, Yoshimura T, Kuo C, Tollenaar RAEM, de Miranda NFCC, Turner RR, van de Velde CJH, Morreau H, **Hoon DSB**. Development of sporadic microsatellite instability in colorectal tumors requires genomic hypermethylation at the premalignant stage. *Am J Pathol*. Epub ahead of print, 2010.
190. Ray P, Wang J, Qu Y, Sim M, Shamonki J, Bagaria S, Ye X, Liu B, Elashoff D, **Hoon DS**, Walter M, Martens J, Richardson A, Giuliano A, Cui X. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. *Cancer Res*, 70:3870-3876, 2010.

191. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, **Hoon DSB**. Direct Serum Assay for microRNA-21 Levels in Early and Advanced Breast Cancer. *Clin Chem (in press)*, 2010.
192. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton, DL, **Hoon DSB**. Down-regulation of MicroRNA-29c is Associated with Hypermethylation of Tumor-Related Genes and Disease Outcome in Cutaneous Melanoma. *Epigenetics*. Epub ahead of print, 2010.
193. Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR, Streck CJ, Whitworth PW, Levine EA, Boolbol S, Han LK, Hermann R, **Hoon DSB**, Giuliano AE, Meric-Bernstam F. Novel Automated Assay for Rapid Identification of Metastatic Breast Carcinoma in Sentinel Lymph Nodes. *Cancer (accepted)*, 2010.

BOOKS

1. Circulating Nucleic Acids in Plasma/Serum III and Serum Proteomics. New York Academy of Science. Eds: **Dave S. B. Hoon**, Bret Taback. Vol. 1022: 2004.

BOOK CHAPTERS AND REVIEWS

1. Cochran AJ, Wen DR, **Hoon DB**, Pihl EA, Fairhurst MV, Korn EL. Tumor proximate immune suppression of regional lymph nodes in patients with malignant melanoma. Ed. Hellmann K and Eccles SA. *In: Treatment of Metastasis: Problems and Prospects*. pp 69-72, 1985.
2. Cochran AJ and **Hoon DB**. Immunological Aspects of Malignant Melanoma. *In: Cutaneous Melanoma. Status of Knowledge and Future Perspective*. Eds: Veronesi CL, Cascinelli N, Santinami M. London: Academic Press, 1987; pp. 47-61
3. Morton DL, Nizze A, Gupta RK, Famatiga E, **Hoon DSB**, Irie RF. Active specific immunotherapy of malignant melanoma. Eds. Kim JP, Kim BS, and Park J-G. *In: Current Status of Cancer Control and Immunobiology*. pp. 152-161. Seoul Press, 1987.
4. Naeim F, Kermani-Arab V, **Hoon D**, Gatti RA, Salser W, Rosenblatt J, Concannon P. Immortalization of T-lymphocytes derived from patients with Hairy Cell leukemia of B-cell type. Recent Advances in Leukemia and Lymphoma, UCLA Symposia on Molecular and Cellular Biology, 61. Eds: Gale RP and Golde DW, 1987.
5. Cochran AJ, Wen DR, Stene M, Fairhurst MV, **Hoon DSB**. Immunobiology of human cutaneous melanoma. Ed. Bagnara JT. *In: Progress in Clinical and Biological Research*, Vol. 256, Advances in pigment cell research. Alan R. Liss Inc., New York, pp. 597-618, 1988.
6. Morton DL, Nizze JA, Gupta RK, Famatiga E, **Hoon DSB**, Irie RF. Active Specific Immunotherapy of Malignant Melanoma. American College of Surgeons, 1988.

7. Cochran AJ, Wen DR, Stene M, Fairhurst MV, **Hoon DS**. Immunobiology of human cutaneous melanoma. *Prog Clin Biol Res*. 256:597-618, 1988.
8. Morton DL, Nizze JA, **Hoon DSB**, Famatiga E, Gupta RK, Irie RF. Active Specific Immunotherapy of Malignant Melanoma: Current Status of UCLA Trials. Ed. A. Albertini, R. Pavlettu, R.R. Reisfeld. *In: Molecular Probes*, Raven Press, New York, pp. 181-189, 1989.
9. Cochran AJ, **Hoon DSB**. Immunobiology of the regional lymph nodes in cutaneous malignant melanoma. Ed. S. Ferrone. *In: Advances in Melanoma Research*, 1989.
10. Morton DL, **Hoon DBS**, Gupta RK, Nizze JA, Foshag LJ, Famitiga E, Furutani S, Irie RF. Treatment of Malignant Melanoma by Active Specific Immunotherapy in Combination with Biological Response Modifiers. Eds. Torisu M and Yoshida T. *In: New Horizons in Tumor Immunotherapy*, Elsevier, Fukuoka, Japan, pp. 665-683, 1989.
11. Morton DL, **Hoon DBS**, Gupta RK, Nizze AJ, Foshag LJ, Irie RF. Melanoma Cell Vaccine. Eds. Balch C, Houghton A, Milton, Sober, Soong. *In: Cutaneous Melanoma (2nd ed)*. Philadelphia, J.B. Lippincott Co., 1991.
12. Morton DL, **Hoon DSB**, Foshag LJ, Nizze A, Gupta RK, Famatiga E, Irie RF. Active immunotherapy of metastatic melanoma with melanoma vaccine and immunomodulation. *Proc Am Assoc Cancer Res* 32, Symposium, pp. 492-494, 1991.
13. **Hoon DSB**, Morisaki T, Uchiyama A, Hayashi Y, Foshag LJ, Morton DL. Augmentation of T cell response with a melanoma cell vaccine expressing specific HLA-A antigens. *Cancer Vaccines. Ann NY Acad Sci*, 690: 343-345, 1993.
14. Morton DL, **Hoon DS**, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. *Ann NY Acad Sci*. 690:120-34, 1993.
15. Morton DL, Nizze AJ, **Hoon DSB**, Foshag LJ, Famatiga E, Gupta RK, Irie RF, and Ramming KP. Improved survival of metastatic melanoma patients receiving active specific immunotherapy with a polyvalent whole-cell vaccine. Ed. S.E. Salmon. *In: Adjuvant Therapy of Cancer VII*. J.B. Lippincott Co., pp. 398-404, 1993.
16. **Hoon DSB**, Morisaki T, Essner R. Interleukin-4 and related cytokines direct effect on growth of non-hemopoietic cancers. In: *Tumor Immunology*. Eds: Dalglish AG and Browning M. New York: Cambridge University Press. Pp. 219-240, 1996.
17. **Hoon DSB**, Irie RF. Current status of melanoma vaccines. Can they control malignant melanoma? *BioDrugs*, Adis International Ltd. 1: 66-84, 1997.
18. Essner R, Nguyen T, Kelley MC Morton DL, **Hoon DSB**. Cell-cycle regulation of human non-small lung carcinoma growth is mediated through functional interleukin-4 receptors (IL-4R) and the interleukin-2 receptor common gamma chain. *Surg Forum XLVIII*: 313-315, 1997.

19. Bilchik A, Miyashiro M, Kuo C, Kelly M, **Hoon D**. Detection of pancreatic carcinoma with a novel multi-marker RT-PCR assay. *Surg. Forum* XLIX, 1998.
20. Fujii S, Irie RF, Okamoto T, Huang S, Morton DL, and **Hoon DSB**. Melanogenesis antigen associated immunity in melanoma and vitiligo patients. 10th International Congress of Immunology. Eds: Talwar GP, Nath I, Ganguly NK, and Rao KVS. In: Monduzzi Editore: 955-958, 1998.
21. Chan AD, Morton DL, Okamoto T, **Hoon DSB**. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? *Biotherapy of Cancer* 3: 44-46, 1999.
22. Nakayama T, Taback B, Nguyen DH, Chi DD, Morton DL, Fujiwara Y, **Hoon DS**. Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients. *Ann N Y Acad Sci.* 906:87-98, 2000.
23. Kaneda Y, **Hoon DS**. DNA vaccines for cancer treatment. *IDrugs.* 4:301-11, 2001.
24. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, **Hoon DS**. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. *Recent Results Cancer Res.* 158:78-92, 2001.
25. Taback B, Giuliano AE, Hansen NM, **Hoon DS**. Microsatellite alterations detected in the serum of early stage breast cancer patients. *Ann N Y Acad Sci.* 945:22-30, 2001.
26. **Hoon DS**, Fujimoto A, Shu S, Taback B. Assessment of genetic heterogeneity in tumors using laser capture microdissection. *Methods Enzymol.* 356:302-9, 2002.
27. Taback B, Shinozaki M, Fujimoto A, Nakayama T, **Hoon DSB**. Microsatellite alterations as diagnostic and prognostic molecular markers in patients with cancer. In: *Cancer Diagnostics: Current and Future Trends*. Eds: Nakamura R, Grody W, Wu J, and Nagle R. Humana Press Inc, pp. 395-428, 2004.
28. Taback B and **Hoon DSB**. Ultrastaging of Melanoma Patients: Molecular Detection of Micrometastatic Disease. In: *Melanoma*. Eds. Thompson J, Morton DL, and Kroon B. Martin Dunitz, pp. 148-163, 2004.
29. Wilson LL, Tran L, Morton DL, **Hoon DS**. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. *Ann N Y Acad Sci.* 1022:317-22, 2004.
30. Taback B, **Hoon DS**. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. *Ann N Y Acad Sci.* 1022:1-8, 2004.
31. Taback B, O'Day SJ, **Hoon DS**. Quantification of circulating DNA in the plasma and serum of cancer patients. *Ann N Y Acad Sci.* 1022:17-24, 2004.
32. Takeuchi H, Fujimoto A, **Hoon DS**. Detection of mitochondrial DNA alterations in plasma of malignant melanoma patients. *Ann N Y Acad Sci.* 1022:50-4, 2004.

33. Taback B, **Hoon DS**. Circulating nucleic acids in plasma and serum: past, present and future. *Curr Opin Mol Ther.* 6:273-8, 2004.
34. Takeuchi H, Wascher RA, Kuo C, Turner RR, **Hoon DS**. Molecular diagnosis of micrometastasis in the sentinel lymph node. *Cancer Treat Res.* 127:221-52, 2005.
35. Martinez SR, Takeuchi H, **Hoon DSB**. The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma. In: *Melanocytes to melanoma: The progression to malignancy*. Eds: Hearing VJ and Leong SP. Humana press, pp. 551-576, 2005.
36. Martinez SR, **Hoon DS**. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony? *J Cell Biochem.* 96:473-83, 2005.
37. Martinez SR, Mori T, **Hoon DS**. Molecular upstaging of sentinel lymph nodes in melanoma: where are we now? *Surg Oncol Clin N Am.* 15:331-40, 2006.
38. **Hoon DS**, Kitago M, Kim J, Mori T, Piris A, Szyfelbein K, Mihm MC Jr, Nathanson SD, Padera TP, Chambers AF, Vantyghem SA, MacDonald IC, Shivers SC, Alsarraj M, Reintgen DS, Passlick B, Sienel W, Pantel K. Molecular mechanisms of metastasis. *Cancer Metastasis Rev.* 25:203-20, 2006.
39. Martinez SR, Mori T, **Hoon DSB**. Molecular Upstaging of Melanoma Lymph Node Metastases: Science Fact or Science Fiction? *North American Surgery Oncology Clinics* 15: 331-340, 2006.
40. Taback B, Saha S, **Hoon DS**. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. *Ann N Y Acad Sci.* 1075:197-203, 2006.
41. Taback B, Giuliano AE, Lai R, Hansen N, Singer FR, Pantel K, **Hoon DS**. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. *Ann N Y Acad Sci.* 1075:211-21, 2006.
42. Umetani N, Hiramatsu S, **Hoon DS**. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. *Ann N Y Acad Sci.* 1075:299-307, 2006.
43. Takeuchi H, Kitago M, **Hoon DS**. Effects of chemokines on tumor metastasis. *Cancer Treat Res.* 135:177-84, 2007.
44. Tanemura A, van Hoesel AQ, Mori T, Yu T, **Hoon DS**. The role of estrogen receptor in melanoma. *Expert Opin Ther Targets.* 11:1639-48, 2007.
45. Sunami E, Vu A, Nguyen SL, Giuliano AE, **Hoon DSB**. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. *Ann N Y Acad Sci.* 1137:171-4, 2008.
46. Amersi F, Giuliano AE, **Hoon DSB**. Molecular Assessment of Sentinel Lymph Nodes. In: *Radioguided Surgery*. Eds. Mariani G, Giuliano AE, pp. 206-217, 2008.

47. Grimm EA, **Hoon DSB**, Duncan LM. Biomarkers for Cutaneous Melanoma. Chapter 43, Cutaneous Melanoma. Eds. Balch C, Houghton A. 5th Ed. 883-97, 2008.
48. Sunami E, Vu A, Nguyen SL, **Hoon, DSB**. Analysis of Methylated Circulating DNA in Cancer Patients' Blood. *Methods Mol Biol*, Ed. Tost, J. 507:349-56, 2009.
49. Nakamura T, Sunami E, Tung N, **Hoon DSB**. Analysis of Loss of Heterozygosity in Circulating DNA. *Methods in Mol Biol*, Ed. Tainsky, M. 520:221-229, 2009.
50. Kitago M, Martinez SR, Mori T, Koyanagi K, Umetani N, Turner R, **Hoon DSB**. Sentinel Lymph Node Chemokine Microenvironment Modulated by Melanoma Metastasis. Chapter 20, *Current Clinical Oncology: From Local Invasion to Metastatic Cancer*, Ed. Leong S. 227-235, 2009.
51. van Hoesel AQ, **Hoon DSB**. Occult Metastases: Detection and Prognostic and Therapeutic Implications. Ch. 4 *Principles and Practice of Surgical Oncology*. Eds. Silberman H., Silberman A. pp. 84-89, 2009.
52. Nicholl M, **Hoon DSB**. Apoptosis in Cutaneous Melanoma. Chapter 5: In: *Apoptosis in Carcinogenesis and Chemotherapy*. Ed. Chen G. Springer, pp. 111-125, 2009.
53. Lessard L, Sunami E, **Hoon DSB**. Circulating Tumor-Related DNA Alterations as Prostate Cancer Biomarkers. In: *Circulating Nucleic Acids in Plasma and Serum*. Ed. Gahan P. Springer, p.p. 21-27, 2011.
54. Nagahara M, **Hoon DSB**. Sex Hormone Receptors and Epigenetics in Breast Cancer. Chapter 3: In: *Female Sex Hormones and Cancers*. Ed. Chen G. Nova Science Publishers, Inc, (*in press*) 2010.
55. **Hoon DSB**, Ferris R, Tanaka R, Chong K, Alix-Panabières C, Pantel K. Molecular Mechanisms of Metastasis. Ed. Leong S. Wiley-Liss, Inc. *The Journal of Surgical Oncology: Review Seminar*. (*in press*) 2010.